Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia
2024-518971-76-00Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by Heidelberg University. Primary endpoint: MR4 after 24 months of ponatinib treatment. Started Nov 2024; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-518971-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518971-76-00.